Tardive Dyskinesia Across Psychiatric Disorders

Download All
Access these interactive, online programs designed to provide the care team with the resources and practical guidance they need to apply the most recent data, guidelines, and expert recommendations for the personalized treatment of their patients with tardive dyskinesia.
Leslie Citrome, MD, MPH
Rif S. El-Mallakh, MD
Joseph F. Goldberg, MD
Sanjay Gupta, MD
W. Clay Jackson, MD, DipTh
Manish Jha, MBBS
John M. Kane, MD
Greg Mattingly, MD
Joseph P. McEvoy, MD
Roger McIntyre, MD, FRCPC
Jonathan M. Meyer, MD
Rebecca S. Roma, MD

Podcasts

Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).

Joseph F. Goldberg, MD Roger McIntyre, MD, FRCPC Released: May 24, 2021

Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.

Leslie Citrome, MD, MPH Joseph P. McEvoy, MD Released: June 11, 2021

John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.

John M. Kane, MD Rebecca S. Roma, MD Released: July 20, 2021

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.

W. Clay Jackson, MD, DipTh Greg Mattingly, MD Released: August 20, 2021

ClinicalThought

The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.

Joseph P. McEvoy, MD Released: May 4, 2021

Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.

Rif S. El-Mallakh, MD Released: June 8, 2021

Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.

Jonathan M. Meyer, MD Released: July 8, 2021

Tardive dyskinesia (TD) has a real-world impact on patient lives. Greg Mattingly, MD, explores the social and emotional impact of TD on patients as well as its prevalence and diagnosis.

Greg Mattingly, MD Released: September 27, 2021

Downloadable Slidesets

Formulate an approach to select the right treatment for patients with tardive dyskinesia.

Manish Jha, MBBS Released: June 17, 2021

Formulate an approach to diagnose patients with tardive dyskinesia.

Greg Mattingly, MD Released: June 21, 2021

Interactive Case Challenge

This eCase explores diagnosis and treatment of tardive dyskinesia in an older female patient with a history of bipolar disorder.

Rebecca S. Roma, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

Neuroscience Research Review: Tardive Dyskinesia Issue 113, September 2021

Two expert faculty members discuss key articles in tardive dyskinesia research and the clinical implications, strengths, limitations, and salient conclusions.

Sanjay Gupta, MD Joseph P. McEvoy, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue